Gujarat Kidney and Super Speciality Ltd (GKSL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Gujarat Kidney and Super Speciality Ltd on NSE and BSE, with an AI summary of each filing.
Unaudited Standalone and Consolidated Financial Results for the Quarter ended September 30, 2026
Outcome · 05 Nov 2026, 12:32 am
Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the unaudited Standalone and Consolidated financial results for the period ended September 30, 2026.
Outcome · 05 Nov 2026, 12:08 am
Gujarat Kidney and Super Speciality Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lacs) ■ Revenue: 3,809 (+194.6% YoY | +11.1% QoQ) ■ EBITDA: 1,022 (+99.4% YoY | +22.0% QoQ) ■ EBITDA Margin (%): 26.8 (-1281 bps YoY | +239 bps QoQ) ■ PAT: 584 (+118.9% YoY | +12.7% QoQ) ■ EPS (INR): 0.74 (+42.3% YoY | +12.1% QoQ)
Earning Con-call
Intimation · 05 Nov 2026, 12:00 pm
Gujarat Kidney & Super Speciality Schedules Q2 FY27 Earnings Call Gujarat Kidney & Super Speciality Limited has scheduled its Q2 FY27 earnings conference call on 5th Nov'26 at 12:00 PM IST, following the announcement of its financial results for the quarter and half-year ended 30th Sep'26. The call will be hosted by Go India Advisors and attended by key leadership, including Chairman & Managing Director Dr. Pragnesh Yashwantsinh Bharpoda, Whole-time Director Dr. Bhartiben Pragnesh Bharpoda, and Non-Executive Director Anitaben Yashvantsinh Bharpoda. Investors can join via universal dial-in numbers +91 22 6280 1557 or +91 22 7115 8383.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2027 and Other business.
Intimation · 04 Nov 2026, 5:30 am
Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Unaudited ....
Intimation · 04 Nov 2026, 5:30 am
Gujarat Kidney And Superspeciality Schedules Board Meeting for Q2 FY27 Results Gujarat Kidney And Superspeciality Limited will convene its Board of Directors meeting on 4th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the company's trading window for designated persons and immediate relatives has been closed effective 1st Oct'26 and will remain shut until 48 hours following the declaration of the financial results.
GUJARAT KIDNEY AND SUPER SPECIALITY LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2027 and Other business.
Intimation · 04 Nov 2026, 5:30 am
Scrutinizer Report for the AGM held on 28.09.2026
Annual General Meeting · 30 Sept 2026, 1:59 am
Outcome of 7th AGM
Annual General Meeting · 28 Sept 2026, 5:09 pm
Corrigendum -Annual Report 2026
Others (Uncategorized) · 19 Sept 2026, 11:44 pm
Notice of AGM to be conducted on 28-09-2026
Annual General Meeting · 04 Sept 2026, 1:40 am
Revised Annual Report
Others (Uncategorized) · 04 Sept 2026, 1:24 am
Annual Report for the Financial year 2025-26
Others (Uncategorized) · 03 Sept 2026, 7:53 pm
Intimation of Pre-Advertisement- Notice of Annual General Meeting of the Company
Annual General Meeting · 01 Sept 2026, 6:49 pm
Intimation of Analyst/ Investor meet on August 31, 2026 on GIA healthcare Day.
Investor Presentation · 28 Aug 2026, 2:32 am
Gujarat Kidney to Participate in GIA Healthcare Day Investor Meet Gujarat Kidney and Superspeciality Limited (GKSL) management will attend the GIA Healthcare Day to meet with investors and analysts. The physical group meeting is scheduled for 31st Aug'26, from 10:00 AM to 11:00 AM at the Jio World Convention Centre, BKC. The company has stated that no unpublished price-sensitive information (UPSI) will be discussed. The short notice for this participation is due to the recent engagement of Go India Advisors as their new IR/PR agency, who organized the event.
Outcome of Board Meeting for Appointment of Additional Director and taking note of resolution approved through Postal Ballot.
Outcome · 25 Aug 2026, 12:13 am
Appointment of Additional Director, subject to confirmation by Shareholders at ensuing Annual General meeting.
Change in Management · 24 Aug 2026, 11:59 pm
Outcome of Board meeting held on 24-08-2026 for appointment of Additional Director, subject to approval of shareholders at ensuing Annual General Meeting and taking note of approval of ....
Others (Uncategorized) · 24 Aug 2026, 11:53 pm
Monitoring Agency Report June 2026
Others (Uncategorized) · 15 Aug 2026, 12:34 am
Gujarat Kidney And Superspeciality: IPO Fund Utilization Report for Q1FY27 As per the monitoring report for the quarter ended 30 Jun'26, Gujarat Kidney has revised its IPO fund allocation objectives via a postal ballot on 25 Apr'26. Of the total ₹250.80 Cr raised, there was zero utilization during the quarter. Key unutilized amounts from the revised plan include ₹17.92 Cr for healthcare expansion, ₹12.62 Cr for inorganic growth, and ₹7.23 Cr for the acquisition of a 51% stake in Blue Tree Clinics, Dubai. Several objects have been completed, while inorganic growth and Dubai acquisition are ongoing.
Statement of Deviation & Variation as on June 30, 2026
Others (Uncategorized) · 15 Aug 2026, 12:27 am
Gujarat Kidney: IPO Fund Utilization & Variation Update for Q1FY27 Gujarat Kidney And Superspeciality Limited reported a variation in the use of its IPO proceeds for the quarter ended 30th Jun'26. The variation, approved by shareholders on 25th Apr'26, pertains to healthcare expansion aligned with its main IPO object. Of the ₹250.80 Cr raised on 24th Dec'25, key unutilized amounts include ₹25.15 Cr for a new hospital in Vadodara and ₹12.62 Cr for inorganic growth. The company confirmed no deviation in utilization from the objects stated in its prospectus.
Financial Results for Quarter ended June 2026
Financial Result · 14 Aug 2026, 11:32 pm
Gujarat Kidney Q1FY27 Results & Board Meeting Update Gujarat Kidney And Superspeciality reported Q1FY27 consolidated results with revenue at ₹34.3 cr, up 126% YoY, and profit after tax at ₹5.3 cr, down 1.5% YoY. On a QoQ basis, revenue grew 11.8% while PAT increased 10.3%. The board also approved the 7th AGM for Sep 28, 2026, and appointed Dr. Paresh Dhoti as an Additional Non-Executive Independent Director, effective Aug 14, 2026, for a five-year term, subject to shareholder approval. Consolidated EPS for the quarter was ₹0.66.
Change in Category of Mr Paresh Dhoti from Additional Director - Non Executive- Non Independent to Additional Director- Non Executive-Independent (appointment shall be subject to approval ....
Change in Management · 14 Aug 2026, 11:08 pm
Gujarat Kidney appoints new Non-Executive Independent Director Gujarat Kidney And Superspeciality Ltd. has appointed Mr. Paresh Dhoti as an Additional Non-Executive Independent Director, effective 14-Aug-26. This changes his prior designation of Non-Executive Non-Independent Director, which was effective from 09-Jul-26. His appointment is for a first term of five years, not liable to retire by rotation, and is subject to shareholder approval. Mr. Dhoti holds a Bachelor of Dentistry (2006) and has 18 years of independent practice. He has no relationships with other company directors.
Outcome of Board meeting for consideration of Unaudited financial results and other matters.
Outcome · 14 Aug 2026, 10:46 pm
Gujarat Kidney and Super Speciality Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) ■ Revenue: 3,429 (+124.7% YoY | +12.1% QoQ) ■ EBITDA: 838 (-2.9% YoY | +33.0% QoQ) ■ EBITDA Margin (%): 24.4 (-3209 bps YoY | +384 bps QoQ) ■ PAT: 518 (+6.9% YoY | +2.8% QoQ) ■ EPS (INR): 0.66 (-22.4% YoY | -18.5% QoQ)
Gujarat Kidney And Super Speciality Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited ....
Intimation · 14 Aug 2026, 5:30 am
Gujarat Kidney to Report Q1 FY27 Results on 14 Aug'26 Gujarat Kidney And Superspeciality Limited will hold a Board of Directors meeting on 14 Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending 30 Jun'26. In accordance with insider trading regulations, the trading window for designated persons has been closed from 01 Jun'26 and will reopen 48 hours after the results are announced. This meeting will provide the first look at the company's performance for the new fiscal year.
Clarification in relation to appointment of Additional Director
Change in Management · 21 Jul 2026, 10:52 pm
Gujarat Kidney Clarifies Director Appointment, Cites Technical Glitch Gujarat Kidney and Super Speciality Limited issued a clarification on 21 Jul'26 regarding its 09 Jul'26 filing. The company stated the intended appointment of Mr. Paresh Dhoti as a Non-Executive Independent Director could not be completed due to a technical glitch with his registration on the IICA database. Consequently, the board has appointed him as a Non-Executive Non-Independent Director effective 09 Jul'26. The company will reconsider his appointment as an Independent Director at a future board meeting once the issue is resolved.